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Abstract
Background: Previous studies have demonstrated that ICU (intensive care unit) survivors have decreased long-term
survival rates compared to the general population. However, knowledge about how to identify ICU survivors with
higher risk of death and the adjustable factors associated with mortality is still lacking.
Methods and Design: The FROG-ICU (the French and European Outcome Registry in Intensive Care Units) study is
a prospective, observational, multicenter cohort study where ICU survivors are followed up to one year after ICU
discharge. Beside one year survival, the study is designed to assess incidence and identifying risk factors for mortality
over the year following discharge from the ICU. All consecutive patients admitted in ICU to the 28 participating centers
during the study period will be included. Every subject will undergo an evaluation at admission, throughout the ICU
stay and at ICU discharge. The global, especially cardiovascular, assessment of each subject will be performed through
a complete clinical exam, instrumental tests (electrocardiogram, echocardiogram) and biological parameters. Blood and
urine samples will be collected at admission and at discharge with the primary goal to assess effectiveness of routine
and novel cardiovascular, inflammatory and renal biomarkers, with potential interest in risk stratification for patients
who survive an ICU stay. The follow up will include a careful tracking of patients through telephone calls and
questionnaires at 3, 6 and 12 months after ICU discharge. FROG-ICU aims to identify the clinical and biological
phenotype of patients with different levels of probability of death in the year after ICU discharge.
Discussion: FROG-ICU has been designed to better understand long term outcome after ICU discharge as well as risk
factors for all-cause and cardiovascular morbidity and associated mortality. It is a large prospective multicenter cohort
with a biological (on plasma and urine) collection and one-year follow-up of ICU patients. FROG ICU will allow
performing a risk stratification of ICU survivors as to recognize the subset of patients who may benefit from an early
intervention to allow decreased cardiovascular morbidity and related mortality.
Trial registration: ClinicalTrials.gov NCT01367093.
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Background
Numerous studies have been designed to investigate the
early mortality of patients admitted in ICU. They focus
on mortality at ICU discharge, at 28 days or/and at hos-
pital discharge [1–3]. Case fatality is high, ranging from
14 to 44 % [1, 4–6] and up to 50 % in septic shock pa-
tients [7, 8]. Although many tools are available to assess
the severity of illness and help clinicians to determine a
prognosis during an ICU stay (Table 1), much less is
known about what happens after ICU and hospital
discharge.
To reduce the mortality rate of ICU survivors, it is im-
portant to identify the group of patients who have a
higher probability of death in the year following ICU
discharge and to recognize the adjustable factors associ-
ated with mortality. Few data have been published re-
garding the long-term outcome of ICU patients, and
most importantly, there are no recommendations for the
long-term management of these patients, only experts
opinion have been published [9, 10]. Some studies have
demonstrated that mortality rates among ICU survivors
are higher compared to the general population [11–15]
and that ICU stay impact on patients’ quality of life
[16]. Moreover, other studies [14, 15] found that this
over-risk of mortality rates is sustained over time per-
sisting after 5 or 15 years of follow-up. Three studies
[11–13] reported a worse survival rate for the ICU pa-
tients than that for the age-matched control population
in the first year after ICU discharge, they also observed
that after 2 to 4 years, the survival curves of the two
groups became parallel.
Table 2 describes the 15 largest studies from the last
30 years, investigating the one-year outcome of ICU
patients and their associated risk factors [11, 13, 15,
17–28]. Using these 15 studies, the pooled estimate of
post-ICU one-year mortality rate was 18.8 % (95 %
confidence interval: 15.1 – 22.5 %), and the corre-
sponding overall mortality (ICU + post-ICU one-year
mortality) was 33.4 % (95 % CI: 27.0 – 39.9 %). How-
ever, only six papers out of fifteen had a prospective
and multicenter study design (most were post-hoc
analyses of prospectively collected data) [11, 19, 20,
23–25]. As expected older age was always associated
with long-term mortality, along with APACHE score
at admission (or within the first 24 h of the ICU stay).
Other factors associated with long-term mortality
were the presence and type of comorbidities and the
cause of ICU admission.
The association between some biomarker plasma
levels and ICU mortality has been studied previously.
Although it has been shown that troponin is frequently
elevated in ICU patients (from 42.1 to 47.3 %) [29, 30],
only 22.2–25.8 % of those patients meet the diagnostic
criteria for myocardial infarction. More importantly,
elevated cTn during ICU stay was associated with an
increased risk of ICU and hospital mortality (OR 2.53;
95 % CI, 1.89 to 3.38) [31–36]. Natriuretic peptide (NPs)
levels were also associated with patients’ outcome. It has
been demonstrated that brain natriuretic peptide (BNP)
level can predict mortality at 6 months after hospital
discharge for patients admitted with acute heart failure
[37]. These results have been confirmed by other
Table 1 The severity of disease classification systems (or risk scores) most frequently used to evaluate the severity of ICU patients
Score Patients Endpoint Measure Reference
Acute Physiolosy and Chronic
Health Evaluation (APACHE)
All ICU patients Hospital mortality Within 24 h of ICU
admission
Knauss WA, 1981, 1985 and 1991
[67–69], Zimmerman JE 2006 [70]
Simplified Acute Physiology
Score (SAPS)
All ICU patients 28-day mortality Once, at 24 h after ICU
admission
Le Gall JR, 1993 [50] and Moreno RP
2008 [71]
Sequential Organ Failure
Assessment (SOFA)
All ICU patients ICU mortality Daily Vincent JL, 1996 [51]
Multiple Organ Dysfunction
(MOD) score
All ICU patients ICU and hospital
mortality
Daily Marshall J, 1995 [72]
McCabe Classification Infective
patients
Hospital mortality At admission McCabe WR, 1962 [52]
Sabadell Score All ICU patients Hospital mortality At discharge Fernandez R, 2006 [73]
Glasgow Coma Scale (GCS) Traumatic brain
injury
Quantify level of
consciousness
Daily Teasdale GM, 1974 [53]
Confusion Assessment method
for the ICU CAM-ICU)
All ICU patients Identify delirium Daily Ely EW, 2001 [54]
Injury Severity Score (ISS) Trauma patients Hospital mortality At admission Baker SP, 1974
Trauma Score Trauma patients Hospital mortality At admission Champion HR, 1981
Lung Injury Score (Murray Score) Lung injured
patients
Quantify the severity
of lung injury
Daily Murray JF, 1988
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Table 2 The 15 largest studies including consecutive ICU patients, reporting one-year outcome and published in the last 30 years
Name Country Study
design
Recruitment period Sample
size
Age (years) Sex (M %) Severity score ICU
mortality
One-year mortality
after ICU discharge
Overall
mortality
Factors associated with
one-year mortality
Zaren B, 1989 [12] Sweden O/P/S 1983 978 53.6 58 N/R 9.6 % 18.7 % 26.5 % age, AC (cardiac arrest, MOF,
neurological or CV disease),
chronic condition (DM,
CHF, cortisone medication)
Dragsted L, 1989 [13] Denmark O/P/S 1979-1983 1308 60 50.6 N/R 18.3 % 29.8 % 42.7 % Age, gender, medical
admission category, cancer
Rochwood K 1993 [14] Canada O/P/M N/R 884 N/R 63.2 18.8 .(APACHE II) 14.4 % 23.5 % 34.5 Age
Niskanen M, 1996 [53] Finland O/P/M 1987 12180 57.2 62.9 11.7 (APACHE II) 9.9 % 20 % 27.9 % Age, gender, emergency
admission, APACHE II at
admission, cancer, CV dz,
RF, GI dz, cardiac arrest
Douglas C, 2002 [15] USA O/P/M Feb 1997 - Mar 1999 538 65.8 56.3 N/R 47.4%a 32.5 % 64.5 % N/R
Keenan SP, 2002 [16] Canada O/R/M Apr 1994- Mar 1996 27103 54.3 57.1 N/R 14.3%a 10.9 %b N/R Age, comorbidity
(lymphoma/leukemia,
HIV, RF)
Kaarlola A, 2003 [17] Finland O/P/S 1995 591 N/R N/R N/R N/R N/R 36 % N/R
Wright JC, 2003 [9] UK O/R/S Jul 1985- Jul 1992 2104 53.6 N/R 14 (APACHE II) 20.6 20.2 36.7 % Age, APACHE II, AC
(hematological and
neurological dz, septic shock)
Bagshaw SM, 2006 [18] Canada O/P/M May 1999 - May 2002 5693 64.9 62 24.9 (APACHE II) 13.4 % 12.9 % 24.5 % Age, medical diagnosis
at admission, APACHE II
score, AKI
Williams TA 2008 [11] Australia O/P/S 1987-2002 22298 61 67 11 (APACHE II) 10.7%a 5.4 % 15.5 % Age, comorbidity, AC, new
diagnosted cancer
Orwelius L, 2010 [19] Sweden O/P/M Aug 2000- Jun 2004 2586 N/R N/R N/R 10.2 % 24 % 31.4 % N/R
Braun A, 2012 [20] USA O/P/M Nov 1997 - Apr 2009 51815 61.7 58.2 N/R 13%a 15.3 % 26.3 % Low preadmission 25(OH)D
level
Meynaar IA, 2012 [21] Holland O/R/S Jan 2004 – Dec 2009 3477 N/R N/R N/R 8.2 % 20.1 % 26.7 % Age, APACHE II, discharge
not toward home
Grander W, 2013 [22] Austria O/P/S Jan 2001- Jun 2004 1086 N/R N/R N/R 9.3 % 15.7 %b N/R HR before ICU discharge
Luangasanatip N, 2013 [23] Thailand O/R/S Jan 2004 - Dec 2005 10321 57.6 N/R N/R 31.5 % 20.7 % 45.7 % AC (cerebrovascular dz,
cancer)
FROG ICU Europe O/P/M From Apr 2011 to
Dec 2013
2250
(expected)
ICU intensive care unit, O observational, R retrospective, P prospective, S single-center, M multi-center, N/R not reported, CPR cardiopulmonary resuscitation, AKI acute kidney injury, WBCC white blood cells count, AC
admission category, MOF multi organ failure, DM diabetes mellitus, CHF chronic heart failure, dz disease, CV cardiovascular, RF respiratory failure, GI gastrointestinal, 25(OH)D 25-idrossicolecalciferolo, HR heart rate
aHospital mortality (ICU mortality was not available)
bMortality rate was extrapolated from a Kaplan-Meier curve
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investigators in heart failure patients admitted to the
ICU [38]. High BNP levels are also associated with 30-
day mortality in septic shock patients [39, 40]. Similarly,
biomarker of inflammation and renal function have been
shown to be associated with mid- and long-term out-
come [41–47].
Thus, measuring cardiovascular, inflammatory and/or
renal biomarkers at ICU discharge could be useful in
early recognition of high risk patients in whom potential
preventive or curative strategies could improve out-
comes. Furthermore measuring biomarkers at discharge
may allow risk stratification of patients for whom close
clinical monitoring as well as chronic life-saving treat-
ments should be introduced. For instance, implementa-
tion of oral beta-blocker at ICU discharge has proven
benefits in acute heart failure patients who were admit-
ted to the ICU for inotropic treatment (dobutamine or
levosimendan) and who received oral beta-blocker ther-
apy at discharge [48]. This has been confirmed on sur-
vival at one year after discharge in ICU patients
admitted for acute respiratory failure [49].
Here, we describe the design of the French and
euRopean Outcome reGistry in Intensive Care Unit
(FROG-ICU), the main objective of which is to assess
the incidence and identify the risk factors of mortality
during the year following discharge from the ICU. This
identification of the risks will be based on the patients’
evaluations throughout their ICU stays, using clinical
and “routine” biological parameters (including creatin-
ine, sodium, potassium, hemoglobin, etc.…) as well as
ICU severity score systems that are already being used
to assess short-term mortality as described in Table 1. In
addition, the effectiveness of novel cardiovascular bio-
markers, including highly sensitive troponin, natriuretic
peptides, sST2 and adrenomedullin (Table 3) to early as-
sess adjustable factors associated with long term mortal-
ity will be evaluated.
Methods and Design
Study design
The French and European Outcome Registry in Inten-
sive Care Units (FROG ICU) study is a prospective, ob-
servational, multicenter cohort study, designed to
assess the incidence and to identify the risk factors of
mortality during the year following discharge from the
ICU. The study will be conducted in France and in
Belgium in accordance with Good Clinical Practice,
Declaration of Helsinki 2002, validated by the ethical
committee (Comité de Protection des Personnes - Ile
de France IV, IRB n°00003835. Comission d’éthique
biomédicale hospitalo-facultaire de l’hôpital de Louvain,
IRB n°B403201213352) and was registed on Clinical-
Trials.gov (NCT01367093). The study consists of two
phases (Fig. 1): initially, all patients admitted to any of
the participating centers during the recruitment period
will be screened for the eligibility criteria listed below;
subsequently, all patients included in the study who
survive to ICU discharge will be followed up for one
year through a telephone call and postal questionnaires
at 3, 6 and 12 months.
Participants
The study will involve 28 medical, surgical or mixed
ICUs in 19 hospitals. The study cohort will include all
consecutive patients who are admitted in ICU to any of
the participating centers during the recruitment period
when the following inclusion criteria are met: invasive
mechanical ventilation support for at least 24 h and/or
treatment with a positive inotropic agent (except dopa-
mine) for more than 24 h. Because the ethical committee
waived the need for written consent, all patients and/or
next of kin will be informed and will orally consent to
participate; consent was documented in the medical rec-
ord by the investigator. Exclusion criteria are the follow-
ing: less than 18 years old; severe head injury (initial
Glasgow Coma Scale < 8) or brain death or a persistent
vegetative state; pregnancy or breastfeeding; transplant-
ation in the past 12 months; not expected to survive or
to leave the hospital; and/or no social security coverage.
Duration of the study and number of participating
centers
The duration of participation for a patient will be a max-
imum of 12 months after ICU discharge. The inclusion
period for any center is 32 months, and we hypothesize
that the average number of patients to be recruited in
each center would be 10 per month. The total study dur-
ation is 44 months.
Study objectives
Primary objective
The primary purpose of this study is to assess the inci-
dence of all-cause mortality in the year following an ICU
stay and to identify the factors associated with mortality;
those factors include both the clinical-biological factors
and the ICU risk scores.
Secondary objectives
The secondary objectives of this study are: 1) to deter-
mine the incidence and the risk factors of cardiovascu-
lar morbidity and mortality in the year following an
ICU stay; 2) to evaluate quality of life in the year fol-
lowing an ICU stay; 3) to assess the role of novel bio-
markers in assessing long-term outcome after ICU
discharge (Table 3).
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Data collection and biological samples
For each patient included, an electronic case report form
will be completed that documents relevant information
about the ICU stay and the one-year follow-up period. At
the time of inclusion, the following will be collected:
demographics, data on past medical history, ICU admit-
ting diagnosis, hemodynamic (non-invasive and invasive)
and respiratory parameters, severity of disease classifica-
tion systems (SAPS-II, SOFA, CAM-ICU, McCabe
Classification and GCS) [50–54]; digital electrocardiogram
(EKG), recorded with CarTouch (Cardionics S.A.,
Bruxelles, Belgium), a high-definition electrocardio-
graph provided with TeleTouch software for the auto-
matic transfer of the EKG to the informatics system.
Routine laboratory tests will be performed. In 9 ICUs,
an echocardiogram will also be performed within a
few hours of inclusion. During the first 3 days of each
ICU stay, respiratory and cardiovascular parameters
(including hemodynamic and EKG) will be recorded
daily and subsequently twice a week; SOFA score will
be performed the first 3 days after inclusion, and rou-
tine biomarkers will be measured according to phys-
ician practice. Renal replacement therapy, death and
cause of death in ICU will be collected.
The following data will be collected at ICU discharge:
clinical parameters, digital EKG and routine biological
assessment, ICU length of stay, duration of mechanical
ventilation, SOFA score, treatment and results of echo-
cardiogram at discharge when performed.
All patients included in the study population who sur-
vive to ICU discharge will be followed up for one add-
itional year or until death, except for severely disabled
subjects (Glasgow Outcome Scale < 4 at discharge). One-
year outcome will be evaluated through data collection
at 3, 6 and 12 months after ICU discharge. At those time
points, patients will be contacted by telephone, and
Table 3 Cardiovascular, inflammatory and renal biomarkers of potential interest in predicting long-term mortality in critically ill
patients
Name Function Clinical interest References
Cardio-vascular biomarkers
copeptine Peptide of stress deriving from
vasopressine
marker of cardiovascular disease Khan SQ, 2007
Proenkephalin endogenous opiod polypeptide hormon marker of cardiovascular and
cerebrovascular disease
Seizinger BR, 1985
Troponin I us part of troponin complex, heart
contraction
marker of myocyte injury Labugger R, 2000
Troponine T hs part of troponin complex, heart
contraction
marker of myocyte injury Labugger R, 2000
Brian natriuretic peptide (BNP) increase of natriuresis and decrease of
vasculare resistance
marker of myocyte stress Davidson NC, 1994
N-terminal pro-BNP (NT-proBNP) biologically inactive segment of BNP marker of myocyte stress Moe GW, 2007
adrenomedullin (ADM) vasodilatation, induction of angiogenesis,
protection against oxydative stress and
hypoxic injury
marker of myocyte stress Khan SQ, 2007
Soluble ST2 involved in cardiac remodeling and
fibrosis
marker of myocyte stress Shah RV, 2010
galectine 3 involved in inflammation, fibrosis and
neoplastic transformation
marker of heart failure de Boer RA, 2009
Biomarkers of infection and/or
inflammation
C-reactive protrine (CRP) acute-phase protein marker of inflammation/infection Elster SK, 1956
Interleukine 6 pro-inflammation and anti-inflammation
cytokine
marker of inflammation/infection Castell JV, 1990
procalcitonin (PCT) precursor of calcitonin marker of infection, mostly bacterial Jones AE, 2007
Renal biomarkers
Plasmatic cystatin C protein derived by all nucleated cells,
readsorbed by proximal tubular cells
marker of decrease glomerular
filtration rate
Roos JF, 2007
Urinary cystatin C protein derived by all nucleated cells,
readsorbed by proximal tubular cells
marker of renal tubular injury Roos JF, 2007
Plasmatic and urinary neutrophil
gelatinase associated lipocain (NGAL)
involve in innate immunity marker of renal tubular injury Kjeldsen L 1993
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information about vital status (patient dead or alive), re-
hospitalization, and cardiovascular morbidity will be re-
corded. For patients lost of follow-up, the vital status
will eventually be checked through the national health
services records when available. In addition, 4 follow-up
questionnaires will be submitted to the study population:
the Hospitalization Anxiety and Depression Scale
(HADS) [55] and the Short Form-36 (SF-36) [56, 57] at
discharge and at 3, 6, and 12 months after and the Im-
pact of Event Scale-Revised (IES-R) [58] at 3, 6 and
12 months; a social questionnaire for assessing patients’
social environments (actual occupation, resumption of
activity, level of income, marital status,…) will be sub-
mitted at 3 months after discharge.
A biological collection will be created with blood
(3x10 ml in EDTA and aprotinin) and urine (10 ml)
samples collected at two different time points: admission
and discharge. The biological collection will allow for
the measurement of novel biomarkers in a central la-
boratory. Table 3 lists the biomarkers with potential
interest for the risk stratification of patient who survive
an ICU stay.
Statistical analysis
Primary analysis will be performed on all patients in-
cluded in the cohort. Only patients who withdrew con-
sent will be excluded. Patients who decided to stop
tracking or who were lost to follow-up will be included
in the analysis. Any missing value will be replaced by
the previous value (the last value carried forward
method). Sensitivity analyses for missing values will be
conducted, for example, using a multiple imputation
(MICE, multiple imputation by chained equations [59].
All tests will be bilateral formulation, with a risk of type
I error of 5 %.
Calculating the number of subjects required is based
on the primary endpoint, i.e., the impact and the risk
factors on one year all-cause mortality. The study of the
literature and the completion of the preliminary inquiry
(conducted in December 2009) in 14 centers that partici-
pated to the study conduct us to assume a 1-year mor-
tality after ICU discharge of 18 %. To ensure detection
with a power of 80 % of binary prognostic factors with a
prevalence of 33 % and an expected OR of 1.5 and a
probability of death of approximately 18 %, 1636 patients
should be included in this study [60]. Assuming a rate of
refusal and/or follow-up losses of 10 %, the number of
patients to be included in the one-year follow-up
amounts to 1800. The expected in-ICU mortality rate is
25 %. Thus, taking into account these results, the num-
ber of patients to be included is 2250.
The primary analysis will be based on the research of
the determinants of 1-year mortality of patients included
in the FROG-ICU (i.e., ICU patients who needed mech-
anical ventilation for more than 24 h and/or treatment
with a positive inotropic agent over 24 and who were
discharged alive from the ICU) among clinical and bio-
logical variables and biomarkers of common interest
(i.e., troponins, natriuretic peptides). The regression
model used will be the logistic model. The log-linearity
of the quantitative variables will be systematically evalu-
ated, and, if appropriate, variable transformations will be
performed. A selection model process will be performed
using stepwise selection method. The selection process
model will be further validated by bootstrap [61]. The
existence of any collinearities will be observed, and a test
of goodness of fit will be performed using the test and
the van Cessie Houwelingen method [62]. Finally a
cross-validation procedure will be performed. The mea-
sures of association will be provided, with odds ratios
and confidence intervals at 95 %. An estimate of related
Fig. 1 FROG-ICU study schema
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risks will also be conducted. Finally, the overall inci-
dence of 1-year mortality will be estimated at a confi-
dence interval of 95 %.
As it is now recognized that highlighting the statisti-
cally significant association between new biomarkers and
patient outcomes is not sufficient to demonstrate the
interest of these biomarkers in terms of risk prediction
[63–65]. We will use the proposed methodology of
Pencina et al., which has been used in multiple articles
of application. For each biomarker of interest, the net re-
classification improvement (NRI) and integrated dis-
crimination improvement (IDI) will be calculated, and
comparisons between different biomarkers will be per-
formed [64].
Regarding quality of life, a strategy similar to that out-
lined for the 1-year mortality analysis will be used to as-
sess its impact and to highlight the predictors of
impaired QoL at 6 months or 1 year. QoL will be esti-
mated using the SF-36 score (ranging from 0 to 100)
[66]. Altered QoL is considered when SF-36 is lower
than 50. In addition, the value of the SF-36 measured in
the FROG ICU study will be compared with the values
that are typically found in healthy populations of the
same age and sex. Interaction between quality of life and
social life will be assessed by using information from the
social questionnaire.
Last, regarding stress and anxiety, as previously de-
scribed, IES-R higher than 30 will define post-traumatic
stress disorder [58] and HADS higher than 8 will defined
anxiety [55]. Similarly, analyses will consist in seeking to
identify risk factors of stress and anxiety after ICU
discharge.
Discussion
Very limited information is currently available concern-
ing the risk factors for long-term survival after a stay in
the ICU. Some studies have investigated the long-term
prognosis of ICU patients [11, 13, 15, 17–28], but only a
few of them have been properly designed to achieve this
result, in a prospective, multicenter manner and using a
large number of patients [11, 19, 20, 23–25]. Few studies
have evaluated biological parameters [25–27] as factors
associated with long-term mortality, and only one study
has correlated the patient’s condition at discharge with
the long-term risk of death [27]. Consequently, at the
moment, there are neither guidelines nor recommenda-
tions to assist clinicians in providing optimal patient
management after ICU.
Accordingly, FROG-ICU is an innovative study that
reflects the endeavor of many ICU physicians to assess
the incidence of all-cause mortality in the year after ICU
discharge and to identify the factors associated with this
mortality. The strengths of the present study are listed
in Table 4: first is the study design because FROG-ICU
is a large observational, prospective and multicenter co-
hort study; second, the evaluation of each patient is per-
formed through a comprehensive clinical assessment,
instrumental tests (electrocardiogram, echocardiogram)
and biological parameters; finally, all of the data are col-
lected at admission, during the stay and at discharge.
Preliminary studies suggest that pre-discharge therapy,
especially the oral administration of beta-blockers, may
improve the survival after an ICU stay [48, 49]. This
would be confirm or not using the FROG-ICU data not-
ably by using causal inference approaches. Moreover all
of these findings favor developing a clinical trial with in-
clusion criteria and number of patients to be recruited
based on the present study, with the main purpose of
decreasing long-term all-cause and particularly cardio-
vascular morbidity and mortality after ICU discharge.
To sum up, FROG-ICU has been designed to better
understand long term outcome after ICU discharge as
well as risk factors for all-cause and cardiovascular mor-
bidity and associated mortality. Because it is a large
prospective multicenter study that collects clinical, bio-
logical and focused cardiovascular biomarkers, FROG
ICU will allow to perform a risk stratification of ICU
survivors as to recognize the subset of patients who may
benefit from an early intervention to allow decreased
cardiovascular morbidity and related mortality. Should
the cardiovascular risks be identified here and validated
in a sub-cohort, a randomized controlled trial using the
results of this risk stratification will be in order to dem-
onstrate survival benefits from a pre- and post-discharge
multifaceted intervention that will include close cardio-
vascular monitoring and oral cardio-vascular therapies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM is the principal investigator of FROG ICU. EG, EV and MRR are the
methodologist/biostatistician of the study. MC was responsible for the
systematic review of the literature and for the writing of the protocol. EA,
BG, SJ, BL and DP are all members of the steering committee and all have
edited the present manuscript. All authors read and approved the final
manuscript.
Table 4 Strengths of the present study
Strengths of FROG-ICU study
Study design Observational, non-interventional, prospective
and multicenter cohort study
Methods for the
evaluation of the patient
Complete clinical assessment, instrumental
tests (electrocardiogram, echocardiogram),
biological parameters and routine
biomarkers during ICU stay
Constitution of a biobank For each patient, plasma and urine will be
collected. For ICU-survivor, urine and plasma
at discharge will also be collected
Repeated evaluations of
the patient
At admission, during the ICU stay, at
discharge and during one year
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